221 related articles for article (PubMed ID: 35653195)
1. Interventional hepatic apoC-III knockdown improves atherosclerotic plaque stability and remodeling by triglyceride lowering.
Ramms B; Patel S; Sun X; Pessentheiner AR; Ducasa GM; Mullick AE; Lee RG; Crooke RM; Tsimikas S; Witztum JL; Gordts PL
JCI Insight; 2022 Jul; 7(13):. PubMed ID: 35653195
[TBL] [Abstract][Full Text] [Related]
2. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans.
Graham MJ; Lee RG; Bell TA; Fu W; Mullick AE; Alexander VJ; Singleton W; Viney N; Geary R; Su J; Baker BF; Burkey J; Crooke ST; Crooke RM
Circ Res; 2013 May; 112(11):1479-90. PubMed ID: 23542898
[TBL] [Abstract][Full Text] [Related]
3. APOC-III Antisense Oligonucleotides: A New Option for the Treatment of Hypertriglyceridemia.
Schmitz J; Gouni-Berthold I
Curr Med Chem; 2018; 25(13):1567-1576. PubMed ID: 28595549
[TBL] [Abstract][Full Text] [Related]
4. Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD.
Taskinen MR; Packard CJ; Borén J
Curr Atheroscler Rep; 2019 May; 21(8):27. PubMed ID: 31111320
[TBL] [Abstract][Full Text] [Related]
5. ApoC-III ASO promotes tissue LPL activity in the absence of apoE-mediated TRL clearance.
Ramms B; Patel S; Nora C; Pessentheiner AR; Chang MW; Green CR; Golden GJ; Secrest P; Krauss RM; Metallo CM; Benner C; Alexander VJ; Witztum JL; Tsimikas S; Esko JD; Gordts PLSM
J Lipid Res; 2019 Aug; 60(8):1379-1395. PubMed ID: 31092690
[TBL] [Abstract][Full Text] [Related]
6. The next generation of triglyceride-lowering drugs: will reducing apolipoprotein C-III or angiopoietin like protein 3 reduce cardiovascular disease?
Reeskamp LF; Tromp TR; Stroes ESG
Curr Opin Lipidol; 2020 Jun; 31(3):140-146. PubMed ID: 32324598
[TBL] [Abstract][Full Text] [Related]
7. ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors.
Gordts PL; Nock R; Son NH; Ramms B; Lew I; Gonzales JC; Thacker BE; Basu D; Lee RG; Mullick AE; Graham MJ; Goldberg IJ; Crooke RM; Witztum JL; Esko JD
J Clin Invest; 2016 Aug; 126(8):2855-66. PubMed ID: 27400128
[TBL] [Abstract][Full Text] [Related]
8. The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans.
Borén J; Packard CJ; Taskinen MR
Front Endocrinol (Lausanne); 2020; 11():474. PubMed ID: 32849270
[TBL] [Abstract][Full Text] [Related]
9. Postprandial distribution of apolipoproteins C-II and C-III in normal subjects and patients with mild hypertriglyceridemia: comparison of meals containing corn oil and medium-chain triglyceride oil.
Barr SI; Kottke BA; Mao SJ
Metabolism; 1985 Nov; 34(11):983-92. PubMed ID: 4058312
[TBL] [Abstract][Full Text] [Related]
10. New medications targeting triglyceride-rich lipoproteins: Can inhibition of ANGPTL3 or apoC-III reduce the residual cardiovascular risk?
Olkkonen VM; Sinisalo J; Jauhiainen M
Atherosclerosis; 2018 May; 272():27-32. PubMed ID: 29544086
[TBL] [Abstract][Full Text] [Related]
11. Expression of human apolipoprotein A-I/C-III/A-IV gene cluster in mice induces hyperlipidemia but reduces atherogenesis.
Vergnes L; Baroukh N; Ostos MA; Castro G; Duverger N; Nanjee MN; Najib J; Fruchart JC; Miller NE; Zakin MM; Ochoa A
Arterioscler Thromb Vasc Biol; 2000 Oct; 20(10):2267-74. PubMed ID: 11031214
[TBL] [Abstract][Full Text] [Related]
12. ApoC-III Glycoforms Are Differentially Cleared by Hepatic TRL (Triglyceride-Rich Lipoprotein) Receptors.
Kegulian NC; Ramms B; Horton S; Trenchevska O; Nedelkov D; Graham MJ; Lee RG; Esko JD; Yassine HN; Gordts PLSM
Arterioscler Thromb Vasc Biol; 2019 Oct; 39(10):2145-2156. PubMed ID: 31390883
[TBL] [Abstract][Full Text] [Related]
13. Lipoprotein distribution of apolipoprotein C-III and its relationship to the presence in plasma of triglyceride-rich remnant lipoproteins.
Marcoux C; Tremblay M; Fredenrich A; Davignon J; Cohn JS
Metabolism; 2001 Jan; 50(1):112-9. PubMed ID: 11172484
[TBL] [Abstract][Full Text] [Related]
14. Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein C-III expression: a potential physiologic basis for their mode of action.
Haubenwallner S; Essenburg AD; Barnett BC; Pape ME; DeMattos RB; Krause BR; Minton LL; Auerbach BJ; Newton RS; Leff T
J Lipid Res; 1995 Dec; 36(12):2541-51. PubMed ID: 8847480
[TBL] [Abstract][Full Text] [Related]
15. New Therapeutic Approaches to the Treatment of Dyslipidemia 1: ApoC-III and ANGPTL3.
Kim JY; Kim NH
J Lipid Atheroscler; 2023 Jan; 12(1):23-36. PubMed ID: 36761060
[TBL] [Abstract][Full Text] [Related]
16. Apolipoprotein C-III: a potent modulator of hypertriglyceridemia and cardiovascular disease.
Kohan AB
Curr Opin Endocrinol Diabetes Obes; 2015 Apr; 22(2):119-25. PubMed ID: 25692924
[TBL] [Abstract][Full Text] [Related]
17. Plasma apolipoprotein C-III levels, triglycerides, and coronary artery calcification in type 2 diabetics.
Qamar A; Khetarpal SA; Khera AV; Qasim A; Rader DJ; Reilly MP
Arterioscler Thromb Vasc Biol; 2015 Aug; 35(8):1880-8. PubMed ID: 26069232
[TBL] [Abstract][Full Text] [Related]
18. ANGPTL3 and ApoC-III inhibitors for treating hypertriglyceridemia in context: horses for courses?
Chan DC; Watts GF
Curr Opin Lipidol; 2024 Jun; 35(3):101-109. PubMed ID: 38372218
[TBL] [Abstract][Full Text] [Related]
19. Common APOC3 variants are associated with circulating ApoC-III and VLDL cholesterol but not with total apolipoprotein B and coronary artery disease.
Silbernagel G; Scharnagl H; Kleber ME; Hoffmann MM; Delgado G; Stojakovic T; Gary T; Zeng L; Ritsch A; Zewinger S; Speer T; Schunkert H; Landmesser U; März W; Grammer TB
Atherosclerosis; 2020 Oct; 311():84-90. PubMed ID: 32949947
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Angiopoietin-Like Protein 3 or 3/8 Complex and ApoC-III in Severe Hypertriglyceridemia.
Larouche M; Khoury E; Brisson D; Gaudet D
Curr Atheroscler Rep; 2023 Dec; 25(12):1101-1111. PubMed ID: 38095804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
